General presentation of Zynerba
Let's take a look at Zynerba Pharmaceuticals and what it does. You need to know all of this before you start trading in order to understand the major issues and potential threats.
The Zynerba Pharmaceuticals Group is an Italian-American pharmaceutical company. Specifically, the group is engaged in the research and development and commercialization of transdermal synthetic cannabinoid treatments for patients with significant unmet needs.
The group has a development pipeline that includes two major product candidates with ZYN002 and ZYN001.
ZYN002 is a synthetic cannabidiol or CBD and a non-psychoactive cannabinoid. It is formulated from a patent-protected gel and enhanced by permeation to allow transdermal delivery through the skin and circulatory system. This treatment candidate is currently in Phase II clinical development and is being tested in patients with refractory epilepsy, osteoarthritis of the knee and Fragile X syndrome.
The other treatment candidate, ZYN001, is a tetrahydrocannabinol or THC prodrug. It allows for transdermal delivery through the skin and into the circulatory system via a patch. This treatment primarily targets two pain indications related to fibromyalgia and peripheral neuropathic pain.
Currently, the Zynerba Pharmaceuticals group has 28 employees.
68% of retail CFD accounts lose money. This is an advert for trading CFDs on eToro